Can Özgür, Koç Gözde, Ocak Sema Berk, Akbay Nursel, Ahishali Emel, Canbakan Mustafa, Şahin Gülizar Manga, Apaydin Süheyla
Department of Nephrology, Haydarpaşa Numune Training and Research Hospital, Tıbbiye Cad. No: 40 Üsküdar, 34668, Istanbul, Turkey.
Department of General Surgery, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey.
Int Urol Nephrol. 2017 May;49(5):889-894. doi: 10.1007/s11255-017-1517-y. Epub 2017 Jan 25.
Gastrointestinal bleeding remains the leading cause of morbidity and mortality for patients who need hemodialysis treatment. Our aim was to evaluate patients who needed hemodialysis and presented with bleeding during their hospital stay (uremic bleeding patients). Factors that increased the risk of bleeding and death were evaluated. Additionally, uremic bleeding patients were compared to non-uremic bleeding patients regarding gastrointestinal findings.
Fifty-one uremic bleeding patients were compared to two control groups which included uremic (hemodialysis dependent and non-bleeding) and non-uremic (no renal insufficiency and bleeding) patients.
NSAIDs and anti-ulcer drug usage were more common in uremic bleeding and in uremic non-bleeding groups, respectively. Dialysis vintage was longer in uremic bleeding group. Comparison of uremic bleeding and non-bleeding uremic patients regarding the usage of ACEI or ARB drugs yielded non-significant results. Acute kidney injury, lower plasma albumin level and high CRP level were significantly increased the risk of mortality in uremic bleeding patients. Hospital stay more than 1 week was the only strong factor for mortality when multivariate analysis was performed. Gastroduodenal and duodenal ulcers were significantly detected in uremic bleeding and non-uremic bleeding patients; respectively.
Hemodialysis patients presenting with gastrointestinal bleeding should be evaluated regarding use of prescriptions and efforts should be done in order to shorten their hospital stay and decrease their mortality. Effect of ACEI or ARB drugs should also be evaluated in future studies.
胃肠道出血仍然是需要血液透析治疗的患者发病和死亡的主要原因。我们的目的是评估需要血液透析且在住院期间出现出血的患者(尿毒症出血患者)。评估增加出血和死亡风险的因素。此外,就胃肠道检查结果而言,将尿毒症出血患者与非尿毒症出血患者进行比较。
将51例尿毒症出血患者与两个对照组进行比较,对照组包括尿毒症患者(依赖血液透析且未出血)和非尿毒症患者(无肾功能不全且出血)。
非甾体抗炎药(NSAIDs)和抗溃疡药物的使用分别在尿毒症出血组和尿毒症非出血组中更为常见。尿毒症出血组的透析龄更长。就血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体阻滞剂(ARB)药物的使用情况而言,尿毒症出血患者与未出血的尿毒症患者比较,结果无显著差异。急性肾损伤、较低的血浆白蛋白水平和较高的C反应蛋白(CRP)水平显著增加了尿毒症出血患者的死亡风险。进行多因素分析时,住院时间超过1周是唯一显著的死亡因素。胃十二指肠溃疡和十二指肠溃疡分别在尿毒症出血患者和非尿毒症出血患者中显著检出。
对于出现胃肠道出血的血液透析患者,应评估其用药情况,并应努力缩短其住院时间并降低其死亡率。未来研究中还应评估ACEI或ARB药物的作用。